The Food and Drug Administration’s Approach to Evaluating Nicotine Replacement Therapies: Public Hearing
FDA White Oak Campus
10903 New Hampshire Ave.
Bldg 31, Rm 1503A
James A. Boiani, Member of the Firm, will speak at a public hearing held by the Food and Drug Administration.
The hearing will discuss the FDA's approach to evaluating the safety and efficacy of nicotine replacement therapy (NRT) products, including how they should be used and labeled.
For more information, please visit FederalRegister.gov.